



1 October 2024

Argent BioPharma Ltd.
(Argent BioPharma or the Company)

Results of Shareholder's General Meeting

Argent BioPharma would like to announce the results from the Company's General Meeting of Shareholders held today, Tuesday, 1 October 2024, in accordance with ASX Listing Rule 3.13.2.

The Company confirms that all motions put to the meeting were voted by poll, with all resolutions carried. Details of the proxy voting and voting outcomes for all motions put to the meeting are set out in the attached report.

Additionally, the Company advises that it is actively progressing towards the appointment of a sponsor, a key step in moving its listing category from Equity Shares (International Commercial Companies - Secondary Listing) to Equity Shares (Commercial Companies) category (ESCC) of the FCA's Official List. Following the appointment of a sponsor, the Company will be in a position to submit an application to the Financial Conduct Authority (FCA) to facilitate the move between listing categories. Once this process is complete, the Company will provide an updated indicative timetable outlining the anticipated ASX delisting timeline, in accordance with the approval granted by shareholders at the General Meeting held today.

There can be no guarantee whether or when an Application to transfer listing category will be approved, in which case there is no guarantee that the Company will delist from the ASX, notwithstanding whether shareholder approval is given. The Company will not delist from the ASX without such approval of the Application to transfer to the ESCC.

-Ends-

Authorised for release by the Company Secretary, for further information please contact:

Argent BioPharma
Roby Zomer
CEO & Managing Director
+61 8 6555 2950
info@argentbiopharma.com

Argent BioPharma
Rowan Harland
Company Secretary
+61 8 6555 2950
info@argentbiopharma.com

About Argent BioPharma

Argent BioPharma Limited (the "Company") (ASX: RGT; LSE: RGT; OTCQB: RGTLF) an innovative multidisciplinary drug development Company within the biopharmaceutical sector. The Company focuses on multidisciplinary methods with Nanotechnology, developing multi-target therapies for comprehensive disease management, especially concerning the central nervous system ("CNS") and Immunology treatments.

Follow us through our social media channels:

LinkedIn: Argent BioPharma
Twitter: @ArgentBioPharma
Facebook: Argent BioPharma

Phone

+61 8 6555 2950

Email

info@argentbiopharma.com

Address

Suite 1, 295 Rokeby Road, Subiaco, WA 6008,
Australia

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

Resolution details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Result
Resolution	Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*	Carried / Not Carried
1 Issue of Shares to Related Party – Roby Zomer	Ordinary	24,895,358 99.60%	97,060 0.39%	2,976 0.01%	11,041	24,911,256 99.61%	97,060 0.39%	11,041	Carried
2 Approval to issue Performance Rights to Brett Mitchell	Ordinary	24,898,204 99.61%	94,215 0.38%	2,975 0.01%	11,041	24,914,101 99.62%	94,215 0.38%	11,041	Carried
3 Delisting from the official list of ASX	Special	24,895,002 99.70%	72,312 0.29%	3,050 0.01%	36,071	24,905,052 99.69%	78,234 0.31%	36,071	Carried
4 Ratification of prior issue of Shares – Listing Rule 7.1	Ordinary	24,920,508 99.71%	69,308 0.28%	3,027 0.01%	13,592	24,936,457 99.72%	69,308 0.28%	13,592	Carried
5 Ratification of prior issue of Shares under the Initial Placement – Listing Rule 7.1A	Ordinary	24,920,450 99.71%	69,392 0.28%	3,001 0.01%	13,592	24,936,373 99.72%	69,392 0.28%	13,592	Carried
6 Ratification of prior issue of Warrants under the Initial Placement - Listing Rule 7.1	Ordinary	24,919,508 99.70%	69,278 0.28%	4,005 0.02%	13,644	24,936,435 99.72%	69,278 0.28%	13,644	Carried
7 Ratification of prior issue of Shares under the Subsequent Placement - Listing Rule 7.1A	Ordinary	16,549,798 99.56%	69,352 0.42%	2,975 0.02%	13,592	16,565,695 99.58%	69,352 0.42%	13,592	Carried
8 Ratification of prior issue of Warrants under the Subsequent Placement – Listing Rule 7.1	Ordinary	16,549,803 99.56%	69,295 0.42%	2,975 0.02%	13,644	16,565,700 99.58%	69,295 0.42%	13,644	Carried

* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.